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Absent Toll-like receptor-9 expression predicts
poor prognosis in renal cell carcinoma
Hanna Ronkainen1*†, Pasi Hirvikoski2†, Saila Kauppila3, Katri S Vuopala4, Timo K Paavonen5, Katri S Selander6,7 and
Markku H Vaarala1,3
Abstract
Background: Toll-like receptor 9 (TLR9) is a cellular DNA-receptor whose activation with cognate ligands triggers
an immune reaction, with increased production of inflammatory cytokines. The aim of this study was to examine
the expression of TLR9 in renal cell carcinoma (RCC), which is generally renowned of its immunogenic nature. We
also evaluated the prognostic value of TLR9 in RCC.
Methods: TLR9 expression in RCC was characterized with immunohistochemistry in a retrospective study
population of 152 RCC patients who underwent renal surgery. The TLR9 staining intensity was compared with
clinical parameters.
Results: Of the studied tumours, 112 (81%) exhibited cytoplasmic TLR9 immunostaining. No association was
detected between cytoplasmic TLR9 immunoexpression intensity and stage, nuclear grade, histological subtype or
tumour necrosis. Cytoplasmic TLR9 immunoexpression was, however, a marker of favourable RCC specific survival
both in univariate analysis and in multivariate regression model.
Conclusions: We conclude that TLR9 expression is an independent prognostic marker of RCC and the absence of
TLR9 expression is related to poorer prognosis in RCC.
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Background
Renal cell carcinoma (RCC) is a cancer of increasing inci-
dence and mortality [1]. At the time of the diagnosis, up
to one third of the patients have metastasized disease and
a half of the remaining patients will experience a recur-
rence after an initially curative treatment [2]. Despite the
many well-known prognostic factors for the disease, the
behaviour of RCC is very difficult to predict.
Toll-like receptors (TLRs) are pattern recognition
receptors that detect both microbe- and host-derived
molecular patterns. Thus far, at least 13 mammalian
TLRs have been recognized, each of them responding to
a different ligand. The subcellular expression sites of the
various TLRs also vary. TLRs 1, 2 and 4 are expressed
and bind their ligands on the cell surface while the TLR9
subfamily (including TLRs 3, 7, 9 and 13) reside in intra-
cellular vesicles. Ligand binding to TLRs activates tran-
scription factors, such as NF-kappaB and the eventual
outcome of TLR activation is an immune reaction, char-
acterized by increased production of inflammatory med-
iators. Specifically, TLR9 is a receptor for both microbial
and vertebrate DNA. The intracellular expression of
TLR9 and also possibly the other endosomal TLRs is
thought to evade self-recognition of DNA and RNA [3-7].
It is now well established that TLR9 is also expressed in
various cancer cells, including breast, brain, ovarian, gas-
tric, lung and prostate cancer cells [8-11]. Furthermore,
in clinical breast, ovarian and prostate cancer specimens,
increased TLR9 expression was associated with decreased
tumour differentiation [10-13]. It has also been demon-
strated that stimulation of TLR9-expressing cancer cells
with synthetic TLR9-ligands increases their in vitro inva-
sion which is associated with the down-regulation of tis-
sue inhibitor of metalloproteinases-3 (TIMP3) and the
up-regulation of matrix metalloproteinase-13 (MMP-13)
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activity. Although bacterial DNA, similar to the synthetic
CpG-sequence containing TLR9-ligands, also induces
invasion in TLR9 expressing cancer cells in vitro, the nat-
ural TLR9-ligand that might induce invasion for example
in breast cancers, remains unknown [10,11].
In the normal kidney, TLR9 expression has been
detected in the renal tubules and interstitial tissue, while
the tubulointerstitial and glomerular expression has
been detected in lupus nephritis [14]. Previously, TLR9
has been associated with renal disease, such as glomeru-
lonephritis [15] and lupus nephritis [16]. To our knowl-
edge, there are no previous studies of TLR9 expression
in RCC. However, the efficacy of a synthetic TLR9-ago-
nist has been studied in a clinical trial in advanced
metastatic RCC. This compound was found to have only
modest antitumour activity [17].
The aim of this study was to investigate TLR9 expres-
sion in RCCs and to evaluate the prognostic significance
of TLR9 immunostaining in RCCs.
Material and methods
Patients
This retrospective clinical cohort consisted of 152
patients with 77 (51%) females and 75 (49%) males who
underwent surgery for primary renal cell carcinoma
between the years 1990 and 1999, at the Oulu University
Hospital. All clinical data and patient follow-up details
were collected from patient records and re-evaluated by
the same urologist (HR). Seven patients (5%) were oper-
ated by resection and 145 (95%) by radical nephrectomy.
At the time of the diagnosis, the median age of the
patients was 63 years old (range 29-86 years) and the
mean age was 62 (SD ± 11 years). The median and mean
follow-up times were 90 (range 0-209) months and 90
(SD ± 63) months, respectively. Complete information
was obtained from all patients. During the follow-up per-
iod, 44 (29%) patients died of RCC, 40 (26%) died of
other causes and 68 (45%) were still alive. The distribu-
tion of the clinicopathological parameters of the tumours
has been previously described [18,19]. Of the patients,
6 (4%) had lymph node metastases and 18 (12%) had dis-
tant metastases. The stage of the tumours was assigned
using the TNM staging of RCC [20]. T and N classes
were determined by the pathological evaluation of pri-
mary tumour and resected lymph nodes. Further, N class
and M class were assessed by radiological evaluation per-
formed before primary operation. The abdominal ultra-
sound was done for every patient and in addition,
abdominal computed tomography (CT) was performed
for 125 patients (82%). Chest radiography (X-ray and/or
CT) was done for 135 patients (89%). In a case of sus-
pected metastases or vena caval involvement, additional
studies such as bone scintigraphy (14 patients, 9%), skele-
tal radiography (17 patients, 11%), magnetic resonance
imaging (MRI) (11 patients, 7%) or cavography (3
patients, 2%) were performed. The study was approved
by the local ethical board.
Tumour samples and TLR9 immunostaining
The tumour samples were routinely fixed in 10% buffered
formalin and embedded in paraffin. The histological diag-
nosis was confirmed by reviewing the haematoxylin and
eosin (H & E) stained original sections simultaneously by
two pathologists. The tumours were re-classified and
graded according to the WHO classification [21]. The
most representative block of the tumour was selected
and cut into 3 μm thick sections, into multi-tissue blocks
which were mounted onto precoated slides. Tissue sec-
tions were then deparaffinized in xylene, rehydrated in
descending ethanol series and washed in phosphate buf-
fered saline (PBS). Expression of TLR9 was analyzed by
using a mouse monoclonal anti-human TLR9/CD289
(Img-305A, clone 26C593.2, Imgenex, San Diego, Califor-
nia, USA, dilution 1:200) antibody, as previously shown
by us [13,22]. In order to enhance the immunoreactivity,
the sections were incubated in a Tris-EDTA buffer (pH
9.0) and boiled. Endogenous peroxidase activity was
eliminated by incubation in hydrogen peroxide and abso-
lute methanol. The bound antibodies were visualized
using Envision Detection System (K500711; Dako Den-
mark A/S). DAB (diaminobenzidine) was used as a chro-
mogen. A multitissue block containing breast cancer
samples and normal cervical tissue was used as a positive
control.
Scoring of TLR9 immunoreactivity
Cytoplasmic TLR9 immunoreactivity was initially scored
according to four cytoplasmic staining intensities: nega-
tive (0), weak (1), moderate (2) or strong (3) [13,22]. For
further statistical analyses, the negative samples (score 0)
were compared with the positive ones (scores 1 to 3).
Immunohistochemical staining was evaluated simulta-
neously by two observers (PH and MHV) who were
blinded to the clinical data and a consensus on the stain-
ing intensity was reached.
Statistical analyses
The software SPSS for Windows 15 (Chicago, IL) was
used for statistical analyses. Associations between factors,
including clinicopathological variables and TLR9 immu-
nostaining patterns, were assessed by the c2 test, or the
Fisher’s exact test in the case of low expected frequencies.
Survival rates were calculated using the Kaplan-Meier
method and the statistical significance between groups
was analysed using the log-rank test. Hazard ratio (HR)
was assessed by Cox univariate analysis. Renal cell carci-
noma-specific survival was calculated from the date of
diagnosis to death from RCC or the last day of follow-up.
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Deaths due to intercurrent causes were censored. Multi-
variate survival analysis was done with the Cox propor-
tional hazards model; the following covariates were
entered: gender, age, stage, Fuhrman grade and TLR9
immunoreactivity. All p-values were two sided.
Results
TLR9 protein expression in RCC
There were 138 RCC tumours available for the evaluation
of TLR9 immunoreactivity. Examples of TLR9 staining
patterns are shown in Figure 1. Twenty-one (15%) of the
tumours were strongly positive, 39 (28%) moderately
positive, 52 (38%) weakly positive and 26 (19%) negative
for cytoplasmic TLR9 immunostaining. For the further
analyses, the weakly, moderately and strongly positive
cases were combined and grouped as TLR9 positive sam-
ples (n = 112, 81%). Some nuclear TLR9 immunopositiv-
ity was also detected in 60 (44%) tumour samples. In
addition to immunoexpression of TLR9 in the tumour
cells, immunoreactivity was observed in endothelial and
inflammatory cells as well as in some fibroblasts.
Association of cytoplasmic TLR9 expression with the
clinicopathological characteristics
The distributions of pT-class, stage, nuclear grade and his-
tological subtype of RCC and their associations with cyto-
plasmic TLR9 expression are presented in Table 1. No
statistically significant associations were detected between
cytoplasmic TLR9 expression and pT-class, stage or grade.
The immunoexpression of TLR9 did not associate with
tumour necrosis (data not shown). There was no associa-
tion between TLR9 expression and histological subtype.
The immunoexpression of TLR9 was common in every
histological subtype of RCC and immunopositivity for
TLR9 was detected in 100 (82%), 6 (67%), 4 (80%) and 2
(100%) cases tumours representing the histological sub-
types of clear cell RCC, papillary RCC, chromophobe RCC
and unclassified RCC, respectively. Nuclear TLR9 expres-
sion did not have any association with these characteristics
(data not shown).
Prognostic significance of TLR9 expression in RCC
The RCC-specific survival was significantly longer for
patients whose tumours did express cytoplasmic TLR9, as
compared with patients whose tumours were negative for
cytoplasmic TLR9 expression (p = 0.007) (Figure 2.). The
hazard ratio (HR) of patients without TLR9-expressing
tumours was 2.40 (95% CI 1.24-4.63, p = 0.009). The
mean RCC-specific survival times for TLR9 negative and
TLR9 positive tumours were 112 (95% CI 76-147) and 160
(95% CI 144-175) months, respectively (p = 0.007)
In the Cox regression analysis for cytoplasmic TLR9
expression, gender, age, stage and nuclear grade, the sta-
tistically significant factors in RCC-specific survival were
stage and TLR9 expression (Table 2).
Discussion
We demonstrate here for the first time that TLR9 is fre-
quently expressed in RCCs. Although there was no asso-
ciation between the immunoexpression of TLR9 and
histological subtype, stage or grade of RCC, cytoplasmic
TLR9 expression was a statistically significant prognostic
factor in RCC specific survival in both univariate and
multivariate analyses and TLR9 expression was an inde-
pendent marker of better prognosis in RCC. Our findings
Figure 1 TLR9 immunostaining in RCC. Tumours with high
cytoplasmic expression (A) and negative cytoplasmic expression (B)
are shown. Magnification ×400, scale bar 50 μm.
Table 1 Associations between cytoplasmic TLR9
expression and tumour pT-class, stage, grade and
histological subtype
Cytoplasmic TLR9 expression
negative positive p-value
pT class
pT1 12 (18%) 56 (82%) 0.31
pT2 4 (36%) 7 (64%)
pT3 8 (15%) 45 (85%)
pT4 2 (33%) 4 (67%)
Stage
I 11 (17%) 52 (83%) 0.27
II 4 (36%) 7 (64%)
III 6 (13%) 39 (87%)
IV 5 (26%) 14 (74%)
Nuclear Grade
I 0 (0%) 5 (100%) 0.69
II 13 (18%) 60 (82%)
III 9 (25%) 27 (75%)
IV 4 (18%) 18 (82%)
Histology
clear cell 22 (18%) 100 (82%) 0.69
papillary 3 (33%) 6 (67%)
chromophobic 1 (20%) 4 (80%)
undifferentiated 0 (0%) 2 (100%)
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thus suggest that the lack of TLR9 confers aggressive
behaviour of renal carcinoma cells. The significance of
nuclear TLR9 expression remains obscure, but it may
also represent unspecific staining.
Expression of TLR9 has been previously detected in
various cancer cell lines and in various clinical cancer
specimens. Synthetic TLR9-ligands induce cancer cell
invasion in vitro and high TLR9 expression has been
associated with poor differentiation of various cancers,
suggesting that high TLR9 expression or naturally exist-
ing DNA-ligands might induce TLR9-mediated invasion,
and thus contribute to worse outcomes in cancers with
higher TLR9 expression. In this light, our finding demon-
strating the lack of TLR9 expression as a poor prognosis
marker is RCC is surprising. So far, the association
between TLR9 and clinopathological parameters and the
survival of cancer patient has been evaluated in only a
few studies. In breast cancer it has been demonstrated
that immunoexpression of TLR9 is significantly increased
in high-grade tumours compared with lower-grade
tumours [12,22]. Similarly, it has been shown that recur-
rent breast carcinomas exhibit a significant increase in
the mRNA levels of TLR9 in cancer cells [23]. However,
a remarkable percentage (57.5%) of recurrent breast
tumours was shown to express TLR9 by fibroblast-like
cells and these tumours have reported to have low prob-
ability of metastasis [23]. It has also been demonstrated
that cell surface stimulation of TLR9 promotes cell pro-
liferation and survival in hepatocellular carcinoma [24].
In neuroblastoma, TLR9 expression has been found to
correlate inversely with disease stage [25] whereas in
glioma, TLR9 expression has shown to be significantly
higher in high grade tumours compared to low-grade
gliomas and TLR9 immunoexpression has been reported
to be a statistically significant marker of poorer prognosis
in glioma [26]. Thus, the contribution of either high or
low TLR9 expression to the pathophysiology of cancer
may be highly tumour specific.
Upon the recognition of DNA, TLR9 recruits specific
intracellular adaptor proteins to initiate signalling path-
ways and the eventual outcome is an immune reaction
characterized by the increased production of inflamma-
tory mediators like interferon and other inflammatory
cytokines [3,27]. RCC is generally renowned of its immu-
nogenic nature. RCC can allure different effector cells of
both the innate and adaptive immune system including
natural killer (NK) cells, dendritic cells (DC) and various
T cells [28]. A variety of tumour-associated antigens
(TAAs) which can evoke tumour-specific T-cell-defined
immune responses in cancer patients has been detected
in RCC tumours [29]. More importantly, immunotherapy
with interferon alpha (IFN-a) or interleukin 2 (IL-2) can
produce even complete and durable response in
advanced RCC [30] and tumour vaccines have shown to
have some response, too [31]. Rare cases of spontaneous
regression of metastases in RCC caused probably by
immunologic mechanism have been reported [32]. Thus,
the prognostic significance of TLR9 expression in RCC
may be associated with immune responses to the tumour
cells. Hypothetically, in the absence of RCC TLR9
expression, such responses are not evoked and they are
less susceptible to immunosurveillance and they can pro-
gress. These issues warrant further investigation.
Low oxygen environments can be created by various
pathophysiological conditions, including infection, inflam-
mation, tissue injury, and solid tumours [33]. Hypoxia is
one of the significant features of solid tumours, including
kidney tumours. Hypoxia and the compensatory hyperacti-
vation of angiogenesis are thought to be particularly impor-
tant in RCC [34]. In hypoxia, an increased expression of
various TLRs including TLR9 has been demonstrated
Figure 2 Associations between cytoplasmic TLR9 expression
and RCC-specific survival. Patients with TLR9 negative tumours
showed reduced survival when compared to patients with tumours
positive for these proteins. p = 0.007
Table 2 Cox multivariate survival analysis in 136 patients
with RCC
Covariate Hazard ratio 95.0% CI p-value
Male gender 0.76 0.45-1.80 0.76
Age 1.02 0.98-1.06 0.34
Stage I 1 (ref.)
Stage II 3.03 0.89-10.3 0.076
Stage III 3.17 1.20-8.35 0.020
Stage IV 19.3 6.86-54.5 < 0.001
Fuhrman grade I or II 1 (ref.)
Fuhrman grade III 1.13 0.49-2.57 0.78
Fuhrman grade IV 2.68 1.20-5.98 0.16
Positive cytoplasmic
TLR9 expression
0.28 0.14-0.58 0.001
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[35,36] and this induction of TLRs has shown to be coordi-
nated by the hypoxia inducible factor 1 (HIF-1) [35].
Whether or not the absence of TLR9 in RCC is regulated
by hypoxia and HIF-1 and thereby, increase the aggressive
behaviour of the tumour cells also warrant further
investigation.
Conclusions
In conclusion, TLR9 immunoexpression is common in
RCC, where it is associated with better prognosis in RCC
and the lack of TLR9 expression in RCC predicts short
survival. The favourable influence of TLR9 expression on
the course of the disease may be based on the immunolo-
gic response generated to the renal carcinoma cells. The
prognostic significance of TLR9 expression in RCC should
be evaluated in other RCC cohorts.
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